Skip to main content
Neuland Labs

Main navigation

  • CDMO Services
    • Small Molecules
    • Peptides
  • Generic APIs
    • API Products
    • Download Brochure
  • Our Capabilities
    • Chemistry & Reactions
    • Peptide Technologies
    • Lifecycle Management (Phase-Appropriate Development)
    • Quality & Regulatory Compliance
    • Technology Transfer
    • Analytical Expertise
    • Process Safety & Engineering
  • Contact us
User account menu
  • Log in

Breadcrumb

  1. Home

2026

By subhendu, 27 October, 2026

Neuland Laboratories Achieves ISO 22301:2019 Certification for Business Continuity Management System (BCMS)

By subhendu, 12 October, 2026

Which Small Molecule API Partner Is Right for Clinical Trials?

By subhendu, 12 October, 2026

What Makes a Peptide CDMO Commercially Ready?

By subhendu, 12 October, 2026

How to Reduce Small Molecule API Manufacturing Delays in 2027

By subhendu, 9 October, 2026

GLP-1 Peptide Manufacturing: A CDMO Buyer's Guide

By admin, 24 September, 2026

Neuland to open $20m* dedicated Process Development facility with integrated kilo labs in Hyderabad

By admin, 24 September, 2026

What to Expect from Neuland Labs at CPHI Milan 2026

By admin, 15 September, 2026

Neuland Accelerates Peptide Manufacturing Expansion with First Commercial Module Operational

By Anonymous (not verified), 3 September, 2026

Pharmaceutical API Stability: Protecting API Quality from Development to Commercial Supply

By Anonymous (not verified), 3 September, 2026

The Complete Drug Development Pipeline: From Discovery to Commercial Scale

Pagination

  • 1
  • Next page
2026
RSS feed
Powered by Drupal